Table 1.
Citation | Cluster | Population description | Description of intervention | Description of control | Intervention duration | Relevant outcomes assessed/results | Adverse events | Quality |
---|---|---|---|---|---|---|---|---|
Metastatic | ||||||||
Pharmacological | ||||||||
Bottomley et al21 | Fatigue, sleep disturbance | 275 patients with metastatic breast cancer patientsb with a median age of 53 years (C) and 52 years (T) (SD = ND) | Doxorubicin 60 mg/m2 as an iv bolus plus paclitaxel 175 mg/m2 as a 3-hr infusion Assessment time points: 2 wks pre-intervention, midpoint (cycles 2, 4, and 6) and EoT (3 mons after the last cycle, with a time window of 10 wks) |
Doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 | Every 3 wks for a max of 6 cycles. | EORTC QLQ-C30 (Fatigue): No significant difference between arms (NS). Across time, fatigue ↑ in both arms by the 2nd assessment. Fatigue ↓ for C arm to levels comparable with baseline. Fatigue remained moderately clinically meaningful in T arm but NS. EORTC QLQ-C30 (Sleep Disturbance): No significant difference between arms or across time (NS). |
More headaches, feeling unwell, dry mouth, and food tasting unusual in both groups | + |
Svensson et al22 | Fatigue, sleep disturbance | 287 female metastatic breast cancer patientsb (≤ Stage II) (mean age = ND) | ET (epirubicin plus paclitaxel): Epirubicin 75 mg/m2 by iv infusion Assessment time points: baseline, 2 mons, and 9 mons |
TEX (epirubicin plus paclitaxel plus capecitabine): Epirubicin 75 mg/m2 by iv infusion Both groups were offered 2nd line treatment with oral capecitabine when the disease progressed | ET: 30-min infusion followed by a 3-hr infusion with paclitaxel 175 mg/m2 TEX: 30-min infusion followed by a 3-hr infusion with paclitaxel 155 mg/m2. 2× daily for 14 days; both treatments Oral capecitabine 825 mg/m2 given repeated every 3 wks for 9 mons. |
EORTC QLQ-C30 (Fatigue): The ET arm scored clinically ↓ than TEX on fatigue at the 2 mons assessment but NS. EORTC QLQ-C30 (Sleep Disturbance): A small clinical difference was found for insomnia in favor of the TEX at the 2 and 9 mons assessments but NS. |
Yes but ND | + |
Hakamies-Blomqvist et al23 | Fatigue, sleep disturbance | 283 female metastatic breast cancer patientsd with a mean age of 52.13 years (T) and 52.16 (C) | Docetaxel 100 mg/m2 Assessment time points: baseline and before each treatment (cycles 2–6) |
MF: sequential methotrexate and 5-fluorouracil at 200 mg/m2 and 600 mg/m2, respectively | TD: Every 3 wks until treatment cycle 6 MF: Given at days 1 and 8 every 3 wks until treatment cycle 6 |
EORTC QLQ-C30 (Fatigue)i: At EoT, TD suffered ↑ fatigue compared to MF (P=0.04). EORTC QLQ-C30 (Sleep Disturbance)i: At EoT, the TD suffered ↑ from insomnia compared to MF (P=0.04). |
Yes but ND | − |
Diel et al24 | Fatigue, sleep disturbance | 466 female breast cancer patientsd (Stage = ND) with a mean age of 54.5±11.5 (C), 55.3±10.9 (2MGIBT) and 56.1±11.4 (6MGIBT) years | 2MGIBT: Ibandronate 2 mg by iv bolus injection 6MGIBT: Ibandronate 6 mg by iv infusion Assessment time points: baseline day before each study visit (Visits 2–5, 8, 11, 14, 17, 20, 23, 26) |
Placebo | 2MGIBT: iv over 1–2 hr at 3–4 wkly intervals limited to a max of 24 treatments for 96 wks 6MGIBT: iv over 1–2 hr at 3–4 wkly intervals limited to a max of 24 treatments for 96 wks |
EORTC QLC-C30 (Fatigue)i: For 6MGIBT, fatigue had ↓ significantly (P<0.05) at the EoT compared with placebo. EORTC QLC-C30 (Sleep Disturbance): Insomnia ↓ in the 6MGIBT compared with placebo, but NS. |
Disease progression, bone pain, and spontaneous bone fracture- | − |
Geels et al25 | Depression, sleep disturbance | 300 female breast cancer patientsb (Stage and mean age = ND) | Doxorubicin 40 mg by iv Assessment time points: baseline and every 3 wks (1st day of each new cycle) |
Doxorubicin 60 mg by iv | ID40: 40 mg/m2 (day 1) plus iv vinorelbine 20 mg/m2 (days 1 and 8) at every 3 wks ID60: 60 mg/m2 day 1 at every 3 wks |
EORTC QLQ-C30 (Depression)i: 60.3% patients showed ↓ depression scores, 26.3% were stable and 13.4% worsened. A positive relationship between likelihood of improvement and objective tumor response (P=0.046). EORTC QLQ-C30 (Sleep Disturbance): Clinical ↓ in sleep disturbance but no significant difference between arms or across time (NS). CRF (Insomnia): Clinical ↓ in insomnia but no significant difference between arms or across time (NS). |
ND | − |
Psychosocial | ||||||||
Bordeleau et al26 | Fatigue, sleep disturbance | 215 female metastatic breast cancer patientsd with a mean age of 49.4±8.4 (T) and 51.5±10.0 (C) years | Supportive-expressive therapy (SET): Supportive-expressive therapy receiving UC plus educational materials about breast cancer and its treatment, relaxation, and nutrition. Assessment time points: baseline, 4 mons, 8 mons, and FU (12 mons) |
UC plus educational materials about treatment, relaxation, and nutrition at every 6 mons | SET: wkly 90-min therapist-led support group + participated in 2-day workshops every 9–12 mons and received monthly reviews of videotapes of randomly selected sessions. | EORTC QLC-C30 (Fatigue)i: A significant across-time deterioration (time effect) in fatigue regardless of study arm (P=0.003).(br)EORTC QLC-C30 (Sleep Disturbance): There were no significant differences across-time (NS). | ND | + |
Williams and Schreier27 | Fatigue, sleep disturbance | 71 breast cancer patientsb (≤ Stage 4) with a mean age of 50.39 (T) and 50.42 (C) years, (SD = ND) | Audiotape on self-care behaviors and SE (SCB): 20-min audiotape that consisted of education about exercise and relaxation to manage anxiety, fatigue, and sleep problems Assessment time points: 1-mon, 3 mons |
Received the standard education and care given to all patients during CHT | The subjects were instructed to listen to the audiotape 12–24 hr before the start of CHT cycles and as often as desired during the course of their treatment. | SCD (Fatigue): There were no significant differences between SCB and control in severity of SE for fatigue (NS). Higher percentage in the control arm than in the SECA arm reported fatigue. The fatigue severity ratings significantly ↑ from the 1st SCD to the 2nd SCD for both arms. Overall fatigue remained a troublesome SE during the study. SCD (Sleep Disturbance): There were no significant differences between the arms in severity of SEs for sleep disturbance (NS). More women in control than in the SCB arm reported difficulty in sleeping whereas the severity significantly increased between the 1st SCD and the 2nd SCD for both arms but NS. |
ND | + |
Low et al28 | Depression sleep, disturbance | 62 female breast cancer patientsh (Stage IV) with a mean age of 53.8±10.3 years | Emotional writing (EMO): Participants wrote at home about cancer-related emotions Assessment time points: baseline, 3 mons |
Control Writing Condition (CTL): Writing facts about diagnosis and treatment | 4 × 20 min sessions for 3 wks | CES-D (Depression): No differences between arms or across time (NS). PSQI (Sleep Disturbance): No differences between arms or across time (NS). |
ND | + |
Multi-modal lifestyle | ||||||||
Targ and Levine29 | Fatigue, depression | 181 female breast cancer patientsf (≤ Stage IV) with a mean age of 49±8.6 (T) and 47±8.8 (C) years | CAM program (CAM): Intensive lifestyle change and group support program with an emphasis on psychospiritual issues, and inner process Assessment time points: pre-test, post-test |
Standard Program (SP): 1.5 hrs/wk unstructured psycho-educational support group led by a psychologist with emphasis on coping with real life issues | 2/wk for 2.5 hrs each time; each wk included 1 hr health series; 90 mins of dance/movement program; experiential work; and 90 min discussion group led by a licensed clinical social for a total of 12 wks. | POMS (Depression)i: Both the CAM arm (P<0.004) and control (P<0.02) showed a significant ↓ in depression at EoT. POMS (Fatigue): No significant difference between arms or across time (NS). |
ND | + |
Non-metastatic | ||||||||
Medical procedures | ||||||||
Bonnema et al30 | Depression, sleep disturbance | 139 female breast cancera patients (≤ Stage II) with a mean age = ND | Short hospital stay: Evaluating the medical and psychosocial effects of short hospital stays after surgery for breast cancer Assessment time points: Baseline, 1-mon after surgery EoT (4 mons); During outpatient visits |
Long Hospital Stay: Effects of long hospital stay after surgery for breast cancer | At admission, patients were given a daily diary, to be used for 1 mon, and a wkly diary to be used for the next 3 mons for a total 4 mons. The length of hospital stay was recorded. | VDBP (Sleep Disturbance): No differences between arms at EoT (NS). VDBP (Depression): No differences between arms at EoT (NS). |
None | + |
Behavioral | ||||||||
Courneya et al31 | Fatigue, depression | 242 breast cancer patientsb (≤ Stages IIIA) with a mean age of 49.2 years, (SD = ND) | Aerobic exercise (AET): Exercise on a cycle ergometer, treadmill, or elliptical Resistance exercise (RET): Exercise performing two sets of 8–12 reps included leg extension, leg curl, leg press, calf raises, chest press, seated row, triceps extension, biceps curls, and modified curl-ups Assessment Time Points: baseline (1–2 wks after starting CHT), midpoint (middle of CHT), EoT (3–4 wks after CHT), and FU (6 mons) |
UC: Offered a 1-mon exercise program after post intervention assessment | AET: 3×/wk for ∼4 wks: duration began at 15 min for wks 1–3. It ↑ by 5 min every 3 wks until the duration reached 45 min at wk 18. RET: 3×/wk: performing 2 sets of 8–12 reps of 9 different exercises. Resistance was ↑ by 10% when participants completed more than 12 reps at wk 18. |
FACT-A (Fatigue): No differences between AET, RET and UC arms (NS). However, for AET adherence (P=0.002) had greater mean changes at EoT compared to UC. CES-D (Depression): No differences between AET, RET and UC arms (NS). However, for adherence to AET (P=0.003) and RET (P=0.019) had greater mean changes at EoT compared to UC; no differences between arms at FU (NS). Effect Size: 0.30 |
Lightheaded, hypotensive, moderately nauseous (n=1), experienced dizziness, weakness and mild diarrhea (n=1) | + |
Wang et al32 | Fatigue, sleep disturbance | 72 Taiwanese breast cancer patientsd (≤ Stage II) with a mean age of 48.40±10.15 years (T) and 52.30±8.84 years (C) | BSET-based: Home-based self-efficacy related exercise (walking) program Assessment Time Points: baseline (24 hrs prior to the surgery), 24 hrs prior to the day of the one cycle of CHT (2–3 wks after surgery), day of expected nadir (7–10 days after CHT), and EoT (6 wks) |
UC | Low to moderate intensity exercise per wk, and at least 30 mins per session or the accumulation of 10-min sessions to reach 30 mins for 6 wks. | FACIT-F (Fatigue)i: Fatigue ↓ in the BSET arm with significant differences between arms at time-3 (P=0.001) and at EoT (P=0.001). PSQI (Sleep Disturbance)i: BSET had significantly ↓ sleep disturbances than those in control over the intervention period (P=0.006). |
Anemia and dizziness with dyspnea (n=2) | + |
Mock et al33 | Fatigue, depression | 52 female breast cancer patientsd (≤ Stage III) with a mean age of 47.14±11.72 years (LW) and 48.64±10.69 (HW) years | Low walk (LW): <90 min of walking/wk + adjuvant CT or RT after breast cancer surgery High walk (HW): >90 min of walking/wk + adjuvant CT or RT after breast cancer surgery. Assessment time points: baseline, 6 wks of RT, and EoT (during 4–6 mons of adjuvant CHT) |
UC | 6 wks of RT and 4–6 mons of CT. Most exercise prescriptions began at 10–15 mins per session and 5–6 sessions per wk. Subjects were advanced to 30 mins per session, 5–6 daily sessions per wk. |
POMS (Fatigue)i: HW had significantly ↓ fatigue at EoT compared to LW (P=0.001). POMS (Depression)i: HW had significantly ↓ depression at EoT compared to LW (P=0.03). Diary (Fatigue)i: Mean fatigue on the daily diaries was significantly ↓ for the HW compared to LW (P=0.001). CHT was significantly ↑ than RT (P=0.01). PFS (Fatigue Total Score)i: HW had ↓ total fatigue at EoT compared to LW but not NS. |
ND | − |
CAM | ||||||||
Listing et al34 | Fatigue, depression | 34 female breast cancer patientsd (≤ Stage II) with a mean age of 59.2±12.1 (T) and 59.9±11.5 (C) years | Classical massage (CM): Swedish techniques while subjects were in prone position Assessment time points: baseline, 5 wks; and FU (11 wks) |
No treatment: wait list | 30 min/day for 5 wks plus FU. | BSF (Tiredness)i: No differences between arms at EoT (NS); CM had ↓ levels of tiredness compared to control at FU (P<0.01). BSF (Anxious Depression)i: CM had ↓ levels of anxious depression compared to control at EoT (P=0.03); no differences between arms at FU (NS). |
Higher level of back pain (n=1), increase in blood pressure (n=1) | ++ |
Listing et al35 | Fatigue, depression | 115 female breast cancer patientsb (≤ Stage II) with a mean age of 57.6±10.8 years (T) and 61.4±10.9 years (C) | Classical massage: Standardized Swedish techniques on back, neck and head Assessment time points: baseline (T1), EoT (5-wks;T2), and FU (11 wks;T3) |
UC: waiting list | 2 × 30 min/wk for 5 wks plus FU. | BSF (Anxious Depression): Anxious depressions between arms were NS. BFS (Tiredness): Tiredness between arms was NS. GBB (Fatigue): Fatigue was ↓ at the EoT between arms but was NS. This positive effect was sustained over time and achieved significance compared with control at FU (P=0.048). Effect Size: 0.3 |
ND | − |
da Costa et al36 | Fatigue, depression | 36 breast cancer patientsc (≤ Stage II) with a mean age of 59 (A) and 57 (B) years, (SD = ND) | Guarana A: Guarana extract daily; before beginning 14th RT, group switched to placebo for remainder of study Guarana B: Received placebo; before beginning 14th RT, group switched guarana daily for remainder of study Assessment time points: Beginning of RT, midpoint of RT, (before the 14th RT session), and EoT (last session of RT or 28th session) |
Placebo: crossover | 75 mg of guarana extract daily for last session of RT or 28th session. | CFS (Fatigue): Fatigue between all arms was NS. MDA BFI (Fatigue): Fatigue between all arms was NS. BDI-II (Depression): Depression between all arms was NS. |
None | − |
Psychosocial | ||||||||
Berger et al37 | Fatigue, sleep disturbance | 219 female breast cancer patientse (≤ Stage IIIA) with a mean age of 52.13 years (T) and 52.16 (C), (SD = ND) | Behavioral therapy (BT): Individualized sleep promotion plan (ISPPr): Modified stimulus control, modified sleep restriction, relaxation therapy, and sleep hygiene Assessment time points: Baseline (2 days prior CT), during the 7 days after each treatment, and FU (30 days after the last treatment) |
HEC: Healthy Eating Control received healthy eating information and attention | Prior to the initial CT, BT participants developed an ISPP plan that was regularly reinforced and revised for 30 days after the last CT, compared with scores prior to the initial treatment. HEC group participants received equal time and attention at each home visit. | PFS (Fatigue)i: Fatigue in both arms changed over time, with ↑ during the treatments and ↓ after treatments ended (P=0.001). The fatigue pattern was similar between the BT and HEC arms (NS). PSQI (Sleep)i: Significant changes in sleep quality in the arms over time (P=0.003). A group by time interaction was found (P=0.04). Sleep quality ↑ significantly in BT arm, but sleep of the HEC arm was more disturbed at treatment 4 and remained more disturbed at FU. Diary (Sleep): Significant ↓ number of awakenings (P=0.032), ↓ WASO-M (P=0.027), and ↑ sleep efficiency P=0.001) in the BT arm over time. But sleep efficiency favoring BT was significant between arms (P=0.075). Effect size: 0.17 |
ND | + |
Cohen and Fried38 | Fatigue, sleep disturbance | 154 female early-stage breast cancer patientsd (≤ Stage II) with a mean age of 55.9±10.4 (CBT), 51.8±11.6 (RGI), and 52.9±11.8 (C) years | Cognitive behavior (CBT): cognitive and behavioral strategies Relaxation and guided imagery (RGI): systematic learning of deep RGI plus deep breathing and autogenic relaxation Assessment time points: preintervention, EoT (3 mons), and FU (4 mons) |
UC | 9 × 90 min sessions/wk for 3 mons plus FU | FSI (Fatigue symptoms): Mean of fatigue symptoms ↓ in both intervention arms (P<0.001) but only the reduction in the RGI arm from pre-to-post intervention appeared significant. Fatigue remained significantly ↓ in the RGI arm than in CB and UC, (P<0.01). Effect Size =0.20 MSQ (Sleep difficulties): Mean of sleep difficulties ↓ in both intervention arms (P<0.001), but only the reduction in the RGI arm from pre-to-post intervention appeared significant. Sleep difficulties remained significantly ↓ in the RGI arm than in CB and UC (P<0.001). Effect Size: 0.10 |
ND | − |
Badger et al39 | Fatigue, depression | 48 female breast cancer patientsf (≤ Stage III) with a mean age of 53.04±8.72 (T) and 54.71±10.34 (C) years | Telephone interpersonal counseling (TIPC): telephone calls from a nurse counselor; sessions focused on issues such as cancer education, interpersonal role disputes, social support, awareness, management of depressive symptoms, and role transitions Assessment time points: baseline, post-intervention (wk 6), and FU (wk 10) |
Usual Care Attentional Control Group (UC): calls from nurse counselor and 3 calls for partner plus resource list | 6 wkly sessions for 6 wks plus FU | CES-D (Depression): No difference between arms or across time (NS). PANAS (Negative Affect): No difference between arms or across time (NS). MFI (Fatigue)i: No significant main effect existed for time. However, a trend was found in the time by group interaction that indicate a ↓ for TIPC arm but not for those in control but NS (P=0.09). |
ND | + |
Sandgren et al40 | Fatigue, depression | 62 female breast cancer patientsd (≤ Stage II) with a mean age of 51.23±12.5 years | Telephone therapy: therapy included providing support, teaching coping skills, managing anxiety and stress, and helping to solve patient-generated problems (eg, interpersonal problems, problems returning to work) Assessment time points: baseline, 4 mons, 10 mons |
No treatment | 1/wk for 4 wks and then every other wk for 10 mons; phone sessions lasted up to 30 mins | POMS (Fatigue): No difference between arms or across time (NS). POMS (Depression): No difference between arms or across time (NS). |
ND | + |
Dolbeault et al41 | Fatigue, depression | 203 breast cancer patientsb with a mean age of 54.5±9.3 (T) and 51.6±9.6 (C) years | Psychoeducationally structured model (PSM): Based on CBT principles, exercises were initiations combined with general medical information and peer exchanges on defined themes; 8–12 participants, led by 2 psychologists or psychiatrists Assessment time points: 1-wk pre-intervention, EoT (8 wks), and FU (1-wk pre-deferred intervention) |
Wait list | 8 × 2 hr sessions/wk for 8 wks pus FU | POMS (Depression)i: PSM had ↓ levels of depression compared to control (P<0.05); depression scores ↓ over time in both arms (P<0.05). POMS (Fatigue)i: Greater ↓ of fatigue in the PSM arm compared to control (P<0.01). EORTC QLQ-C30 (Fatigue)i: Greater ↓ of fatigue in the PSM arm compared to control (P<0.01). POMS Global (Negative Affect)i: A greater reduction of negative effects were observed in the TG compared with the CG arm but NS. |
ND | + |
Multimodal lifestyle | ||||||||
Lindemalm et al42 | Fatigue, depression | 41 female low-stage breast cancer patientsd with a mean age of 56.5 (T) and 66 years (C), (Stage and SD = ND) | Support group program CT-RT: Support team + adjuvant-combined CT and RT Support Group Program RT: Support team + adjuvant RT only Assessment time points: Pre-intervention, and FU (2 mons, 6 mons, 12 mons) |
UC | From Sunday to Saturday on a residential basis followed by 4-days and FU (2 mons after initial visit) | NFQ (Fatigue)q: No difference between arms (NS); both arms showed significant ↓ of total fatigue (P=0.01) and physical fatigue (P=0.015) over time compared to control. HADS (Depression)q: No differences between arms or across time (NS). |
ND | − |
Mixed | ||||||||
Pharmacological | ||||||||
Roscoe et al43 | Fatigue, depression | 122 female breast cancer patientsb (Stage = ND) with a mean age of 52.2±9.3 (T) and 52.2±10.2 (C) years | Paroxetine: 20 mg Assessment time points: Cycle 1–4 of CHT |
Placebo | Daily starting 7 days after 1st on-study treatment (1st cycle of CHT) and stopping 7 days after 4th on-study treatment (4th cycle of CHT) | CES-D (Depression)i: Paroxetine had greater effective than control in ↓ depression across all CHT cycles (P<0.001); paroxetine arm (P<0.01) showed a significant ↓ in depression between treatments 1 and 4 while control showed no significant differences (NS). POMS-DD (Depression)i: Paroxetine (P<0.01) and control (P=0.03) both showed significant ↑ in depression between treatments 1 and 4 POMS-FI (Fatigue): There were no significant differences between arms at any time point (NS). FSCL (Fatigue): There were no significant differences between arms at any time point (NS). MAF (Fatigue): There were no significant differences between arms at any time point (NS). |
Nausea and headache | + |
Psychosocial | ||||||||
Thornton et al44 | Fatigue, depression | 45 female breast cancer patientsd (Stage II, III) with a mean age of 50±11.6 (C) and 50±8.6 (T) years | Psychological intervention: conducted in groups of 8–12 patients led by two psychologists; Assessment time points: baseline, 4 mons, 8 mons, 12 mons |
No treatment | Two sessions over 12 mons consisting of 4 mons of 1.5 hr sessions (intensive phase) followed by 8 monthly sessions (maintenance phase) | CES-D (Depression)i: Depression symptoms ↓ faster over time for psychological arm when compared to control (P<0.04). POMS (Depression)i: Depression ↓ faster over time for psychological arm when compared to control (P=0.02). POMS (Fatigue)i: The psychological arm showed greater ↓ in fatigue over time when compared to control (P=0.048) |
ND | + |
Sandgren and McCaul49 | Fatigue, depression | 235 female breast cancer patientsd (≤ Stage III) with a mean age of 54.5±11.8 years | Cancer health education (CHE): Structured curriculum presented by the nurse with time for brief discussion and questions. Emotional expression therapy (EET): Same number of calls from the same nurses; nurses instructed patients to feel free to explore their emotions and the things that are on their mind Assessment time points: pre-intervention, and FU: approx 5-mons |
UC | Both interventions: 5 × 30 min phone calls/wk, plus 6th FU call at 3 mons | POMS (Fatigue): No differences between the CHE, EET, and control arms (NS); pooled analyses show no differences across time (NS). POMS (Depression)i: No differences between the CHE, EET, and control arms (NS), pooled analyses show an improvement in depressed scores over time (P<0.01). |
ND | + |
Sandgren and McCaul45 | Fatigue, sleep disturbance | 237 female breast cancer patientsd (≤ Stage III) with a mean age of 54.4 years, (SD = ND) | Health education group (HET): topics included: 1) understanding breast cancer, 2) managing post-surgical changes, 3) understanding treatment, 4) managing treatment side effects and fatigue, 5) healthy lifestyle, and 6) FU review. Emotional expression therapy (EET): nurse instructed patients to describe their thoughts and feelings about breast cancer, and any emotional issues about breast cancer Assessment time points: pre-test, 6 mons, 13 mons |
No treatment: not restricted from participating in community support groups, receiving mental health care or using standard clinic nurse helpline | Both interventions: 5 × 30 min phone calls/wk, plus 6th FU call at 3 mons. Seven oncology nurses delivered both interventions for a total 13 mons |
POMS (Depression)i: No differences between the HET, EET and control arms (NS), combined group scores show a decrease in depression over time (P<0.03). POMS (Fatigue)i: No differences between the HET, EET and control arms (NS), combined group scores show a ↓ in fatigue over time (P<0.03). |
ND | + |
Survivors | ||||||||
CAM | ||||||||
Jain et al46 | Fatigue, depression | 76 breast cancer survivors (≤ Stage IIIA) with a mean age of 52 (BH), 52 (MH) and 19 (C) years, (SD = ND) | Biofield healing (BH): practitioner practices hands-on healing with standard hand positions for 45–60 min (energy chelation technique) Mock healing (MH): delivered by practitioners who were skeptical scientists trained to use the identical hand placements as biofield healing practitioners Assessment time points: pre-intervention, post-session 2, midpoint, post-session 6, and EoT (4 wks) |
Waitlist | Two sessions/wk × 4 wks | MFI (Fatigue)i: Both the BH (P<0.0005) and MH (P=0.02) arms had a greater ↓ in fatigue symptoms than the control. There were no significant changes in fatigue for control (NS). Effect size: Biofield healing vs Control (d=1.04), Mock healing versus control (d=0.68) CES-D (Depression): There were no significant interactions (NS). |
None | ++ |
Behavioral | ||||||||
Lee et al47 | Fatigue, depression | 50 breast cancer survivors with a mean age of 47.5±5.1 (SSEP), 45.6±7.0 (GEP) and 47.6±9.2 (C) years | Both training interventions: include stretching and strengthening Scapula-oriented shoulder exercise program (SSEP): Adopted from scapular mobilization exercises for shoulder dyskinesis and kinetic chain-based shoulder rehabilitation. Participants were asked to do exercises from simple motions to advanced strengthening. General Exercise Program (GEP): regular exercise program for shoulder and whole body Assessment time points: 1 and 4 wks after the EoT for 8-wks |
UC: A leaflet guiding self-care including general shoulder range of motion exercise after surgery was provided as a UC | Gradually with an interval of 2 wks for a total 8 wks | EORTC QLQ-C30 (Fatigue)i: No differences between SSEP, GEP and control arms (NS); fatigue scores of GEP arm ↓ at FU (P=0.027); no differences over time were seen in the SSEP (NS) or control (NS). BDI (Depression): No significant differences between arms or across time (NS). |
Shoulder discomfort (scapula-oriented exercise group) | ++ |
Multimodal lifestyle | ||||||||
Kim et al48 | Fatigue, depression | 45 female breast cancer (≤ Stage III) survivors with a mean age of 44.6±9.9 (T) and 47.1±7.3 (C) years | Simultaneous stage-matched exercise and diet (SSED): Stage-matched telephone counseling complimented with a workbook, individualized prescription for regular moderate exercise, a balanced diet program, exercise and diet prescriptions Assessment time points: baseline and wk 12 |
ND | Delivered wkly during 30 min telephone counseling session for 12 wks | BFI (Fatigue)i: SSED arm had greater ↓ in fatigue levels compared to control (P=0.001). HADS (Depression)i: SSED arm had greater ↓ on depression scores compared to control (P=0.035). |
ND | + |
Notes: 31% of the studies did not have sufficient statistical power and 41% of studies did not report a power calculation:
patients receiving surgery;
patients receiving chemotherapy;
patients receiving radiation;
patients receiving surgery, chemotherapy, and radiation;
patients receiving surgery and chemotherapy;
patients receiving chemotherapy and radiation;
patients receiving hormone therapy;
treatment received not described;
effect size not reported.
Abbreviations: 95% CI, 95% Confidence Interval; BDI, Beck Depression Inventory; BFI, Brief Fatigue Inventory; BSF, Berlin Mood Questionnaire; C, control Group; CBT, Cognitive Behavioral Therapy; CES-D, Center for Epidemiological Studies-Depression Scale; CFS, Chalder Fatigue Scale; CHT, chemotherapy; CRF, Case Report Form; EORTC QLC-C30, European Organization for Research and Treatment of Cancer Health Related Quality of Life Questionnaire; EoT, end of treatment; FACIT-F, Functional Assessment of Chronic Illness Therapy; FACT-A, Functional Assessment of Cancer Therapy-Anemia; FSCL, Fatigue Symptom Checklist; FSI, Fatigue Symptom Inventory; FU, follow-up; GBB, Geissen Complaints Inventory; GHQ, General Health Questionnaire; HADS, Hospital Anxiety Depression Score; HDRS, Hamilton Depression Rating Scale; hr, hour; HSCL-25, Hopkins Symptom Checklist-25; iv, intravenous; ISI, Insomnia Severity Index; MAF, Multidimensional Assessment of Fatigue; Max, maximum; MD, mean difference; MDA BFI, Anderson Brief Fatigue Inventory; MFI, Multidimensional Fatigue Inventory; Min, minutes; Mon(s), month(s); MSQ, Mini Sleep Questionnaire; NCI-CTC, National Cancer Institute Common Toxicity Criteria; ND, not described; NFQ, Norwegian Fatigue Questionnaire; NS, not significant; PANAS, Positive and Negative Affect Scale; PFS, Piper Revised Fatigue Scale; POMS-DD, Monopolar Profile of Mood States; POMS, Profile of Mood States; PSQI, Pittsburgh Sleep Quality Index; QOL, quality of life; RT, radiation therapy; reps, repetitions; SAS, Self-rating Anxiety Scale; SCD, Self Care Diary; SD, standard deviation; SE, side effect; T, treatment group; SIGN, Scottish Intercollegiate Guidelines Network; UC, usual care; VDBP, van den Borne and Pruyn; wk(s), week(s); wkly, weekly.